

Special Issue

HPV Vaccines and New Vaccination Schedules Implementation

Message from the Guest Editors

Human papillomavirus (HPV) vaccination programs are a primary prevention strategy for cervical cancer. They have made significant progress in preventing HPV-related diseases. Countries that have implemented these vaccination efforts have observed substantial reductions in HPV-related conditions, including decreases in high-grade cervical neoplasia and genital warts. However, global coverage remains imbalanced, with notable disparities between high-income and low-income countries. While effective programs exist, they remain suboptimal, thus the World Health Organization's strategy to eradicate cervical cancer faces an uncertain future.

This Special Issue aims to provide insights into **HPV vaccines and the burden of HPV-related diseases, including updates on HPV vaccine efficacy, HPV-related disease prevention, the status of HPV vaccination coverage, and estimates of the time required to meet vaccination targets in various countries. It will also examine barriers to HPV vaccination and address other issues surrounding the HPV vaccine.** We welcome original research articles and reviews broadly covering these topics.

Guest Editors

Dr. Kirvis Torres-Poveda
Dr. Aurelio Cruz-Valdez
Dr. Vicente Madrid-Marina

Deadline for manuscript submissions

31 December 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/235259

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).